3,652
Views
5
CrossRef citations to date
0
Altmetric
Research Article

Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial

, , , , , , , , & show all
Article: 2190430 | Received 13 Dec 2022, Accepted 09 Mar 2023, Published online: 05 Apr 2023

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.